IGFBP7 for diagnosing diastolic dysfunction

Patent metadata

Field	Value
Publication number	US-10345315-B2
Application number	US-201615274533-A
Country	US
Kind code	B2
Filing date	Sep 23, 2016
Priority date	Mar 26, 2014
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.

First claim

The invention claimed is:

1. A method for diagnosing and/or grading diastolic dysfunction and/or at least one structural or functional abnormality of the heart associated with diastolic dysfunction in a patient suffering from heart failure, said method comprising the steps of
a) obtaining a plasma or serum sample from a human patient suffering from heart failure,
b) measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) in the sample from a patient suffering from heart failure, said patient having a reduced left ventricular ejection fraction (LVEF), and
c) comparing the level of IGFBP7 measured in a) to a reference level,
wherein the structural or functional abnormality associated with diastolic dysfunction is selected from the group consisting of an increased E′/A′ ratio, increased left atrial size, increased left atrial volume index, increased E peak velocity, decreased A peak velocity, increased transmitral E/A ratio, increased E/E′ ratio, decreased pulmonary vein systolic peak velocity, increased pulmonary vein diastolic peak velocity, decreased pulmonary vein systolic/diastolic ratio, increased right ventricular area, increased right ventricular systolic pressure (RVSP), increased right ventricular dilation, increased right atrium size, a more than mild mitral regurgitation, and a more than mild tricuspid regurgitation, and
wherein the level of biomarker is measured using a sandwich immunoassay, and
d) administering a drug to treat a diastolic dysfunction and/or at least one structural or functional abnormality associated with diastolic dysfunction, wherein the drug is Spironolactone, Sildenafil and/or Anakinra.

2. The method according to claim 1 , wherein the patient suffers from heart failure stage C or D according to ACC/AHA classification, and/or from heart failure NYHA class III or IV according to NYHA classification.

3. The method according to claim 1 , wherein the patient has a LVEF of less than 50%.

4. The method of claim 1 , wherein the patient has left ventricular hypertrophy.

5. The method of claim 1 , wherein the patient suffers from heart failure due to left ventricular systolic dysfunction.

6. The method according to claim 1 , wherein diastolic dysfunction and/or at least one structural or functional abnormality associated with diastolic dysfunction is diagnosed, and wherein
a) a level of IGFBP7 above the reference level indicates that the patient suffers from diastolic dysfunction and/or said at least one structural or a functional abnormality associated with diastolic dysfunction, and/or
b) a level of IGFBP7 below the reference level indicates that the patient does not suffer from diastolic dysfunction and/or said at least one structural or a functional abnormality associated with diastolic dysfunction.

7. The method according to claim 1 , wherein diastolic dysfunction and/or at least one structural or functional abnormality associated with diastolic dysfunction is graded, and wherein
a) a level of IGFBP7 above the reference level indicates that the patient suffers from a severe form diastolic dysfunction and/or a severe form of said at least one structural or functional abnormality associated with diastolic dysfunction, and/or
b) a level of IGFBP7 below the reference level indicates that the patient suffers from a mild form of diastolic dysfunction and/or a mild form of said at least one structural or functional abnormality associated with diastolic dysfunction.

8. The method according to claim 1 , wherein the method further comprises the steps:
a(i) of measuring the level of at least one further biomarker selected from the group consisting of Osteopontin, a cardiac Troponin, B-type natriuretic peptide (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP), Endostatin, Mimecan, uric acid, and GDF15 (Growth differentiation factor 15) in the sample from the patient, and
b(i) comparing the level to a reference level.

9. The method according to claim 1 , wherein the patient has a LVEF of less than 40%.

10. The method of claim 1 , wherein the patient has a left ventricular mass index larger than 126 g/m2.

Assignees

• Roche Diagnostics Operations Inc

Inventors

• Karl Johann
• Wienhues-Thelen Ursula-Henrike
• Block Dirk
• Zaugg Christian
• Brunner Hans-Peter
• Januzzi James
• Ziegler Andre
• Braz Julian
• Dieterle Thomas
• Kaiser Edelgard

Classifications

• G01N2800/325

  Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure · CPC title

• G01N33/6887 Primary

  from muscle, cartilage or connective tissue · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title

• G01N2333/47

  Assays involving proteins of known structure or function as defined in the subgroups · CPC title